Skip to main content

Advertisement

Table 1 Clinical features and baseline plasma lipid concentrations of the two groups of subjects with primary hypercholesterolemia (HCH) treated with BBR/P/RR or EZE for six months

From: Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

  BBR/P/RR EZE P
Males/Females 62/90 31/45  
Age (years) 57.3 ± 12.1 58.3 ± 12.3 NS
BMI (kg/m2) 23.9 ± 2.9 23.5 ± 2.8 NS
Arterial hypertension 30.2% 31.5% NS
Carotid atherosclerosis* 26.3, 48.0, 3.9% 31.5, 51.3, 3.9% NS
TC (mmol/L) 7.63 ± 0.50 7.72 ± 0.49 NS
LDL-C (mmo/L) 5.36 ± 0.48 5.36 ± 0.52 NS
HDL-C (mmo/L) 1.55 ± 0.35 1.57 ± 0.34 NS
non-HDL-C (mmol/L) 6.07 ± 0.54 6.15 ± 0.55 NS
TG (mmol/L) 1.46 (1.22-1.90) 1.67 (1.24-2.12) NS
  1. *Percent of subjects with increased intima-media thickness, with fibrous-calcific plaques with less than 30% stenosis and with fibrous-calcific plaques with 30-40% stenosis, respectively. Median (interquartile range). NS: not significant.